Podcasts about duke university school

Check out the video version of this episode on HCPLive!Finerenone's expansion into non-diabetic kidney disease is prompting a broader rethink of how chronic kidney disease is measured, mechanistically understood, and treated across its many causes.On an episode of Don't Miss a Beat recorded at the 10th Annual Heart in Diabetes Meeting, hosts Stephen Greene, MD, meeting co-chair and heart failure specialist at Duke University School of Medicine, and Muthiah Vaduganathan, MD, MPH, codirector of the Center for Cardiometabolic Implementation and cardiologist at Brigham and Women's Hospital, spoke with Katherine Tuttle, MD, professor of medicine at the University of Washington, about the phase 3 FIND-CKD trial and how it informs on the overall role of finerenone (Kerendia) in management of cardiovascular-kidney-metabolic syndrome.FIND-CKD showed finerenone slowed total estimated glomerular filtration rate (eGFR) slope by 0.7 mL/min/1.73 m² per year versus placebo, irrespective of diagnosis. Much of the discussion focused less on the number and more on why it counts as clinically meaningful.Drawing on CKD Prognosis Consortium data from hundreds of thousands of patients, Tuttle explained why eGFR slope reliably predicts kidney failure when a trial runs at least 2 years. CKD progresses rather than striking as a discrete event, so the field has moved toward endpoints measurable without waiting for organ failure or death.On safety, hyperkalemia occurred more often with finerenone than placebo, about 12% versus 3%, though fewer than 1% of patients discontinued. The framing was practical, with background SGLT2 inhibition expected to lower the risk.Mechanism anchors much of the conversation between Tuttle, Greene, and Vaduganathan.Tuttle highlighted how glomerular diseases, like IgA nephropathy, are immunologic disorders needing disease-specific therapy, yet all CKD converges on shared final common pathways of inflammation and fibrosis. Broad agents like finerenone target those pathways, making combination therapy the emerging model, pairing treatment of the inciting disease with control of progression.The group also discussed the field's trend toward precision nephrology. Protocol biopsies from the Kidney Precision Medicine Project showed only about half of patients labeled as diabetic CKD had classic diabetic nephropathy. A parallel to oncology followed, where deep phenotyping replaced uniform regimens, suggesting not every patient will need every drug.Tuttle positioned finerenone alongside renin-angiotensin system inhibitors and SGLT2 inhibitors as an emerging pillar for non-diabetic CKD, with GLP-1 receptor agonists and endothelin antagonists possibly to come. A pooled analysis of FIDELIO-DKD, FIGARO-DKD, and FIND-CKD showed roughly 30% reductions in kidney and cardiovascular outcomes and an 11% drop in all-cause mortality. The closing point held the cardiorenal patient often arrives through either specialty's door, making preservation of organ function and quality of life the shared aim.Relevant disclosures for Tuttle include Alnylam, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GSK, Novo Nordisk, Roche, and Travere Therapeutics. Relevant disclosures for Vaduganathan include Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others. Relevant disclosures for Greene include Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others.References: Heerspink HJL, Neuen BL, Agarwal R, et al. Finerenone in Persons with Chronic Kidney Disease without Diabetes. N Engl J Med. Published online June 4, 2026. doi:10.1056/NEJMoa2604625 Bayer. Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026. Bayer.com. Published June 2, 2026. Accessed June 21, 2026. https://www.bayer.com/en/us/news-stories/kerendia-in-non-diabetic-chronic-kidney-disease

Humans have five senses, but for most of us, sight dominates. That's why vision problems are so distressing. Have you been dealing with difficulties with your eyes? During this broadcast episode, our guest expert is ready to answer your questions about vision problems. At The People's Pharmacy, we strive to bring you up to date, rigorously researched insights and conversations about health, medicine, wellness and health policies and health systems. While these conversations intend to offer insight and perspective, the content is provided solely for informational and educational purposes. Please consult your healthcare provider before making any changes to your medical care or treatment. How You Can Listen You could listen through your local public radio station or get the live stream at 7 am EST on Saturday, June 20, 2026, through your computer or smart phone (wunc.org).  Here is a link so you can find which stations carry our broadcast. If you can't listen to the broadcast, you may wish to hear the podcast later. You can subscribe through your favorite podcast provider, download the mp3 using the link at the bottom of the page, or listen to the stream on this post starting on June 22, 2026. On this episode, we will be taking calls from listeners. You can ask your question ahead of time by emailing radio@PeoplesPharmacy.com. Or call 888-472-3366 directly between 7 and 8 am EDT on Saturday, June 20, 2026. Are More People Nearsighted? Myopia, the technical term for nearsightedness, is increasing at a rapid rate. Globally, 23 percent of the world’s population had myopia in 2000. By 2020, that rate had risen to 34 percent. Some experts estimate that it could reach 50 percent by 2050. Rates among children and adolescents are even higher in some places, reaching 70 percent among East Asians and an alarming 86 percent among Singaporean Chinese youth 15 and under (British Journal of Ophthalmology, July 2016).  Why are so many people, including young people, myopic? Are there implications beyond a need for corrective lenses (glasses or contacts)? Can we reverse this trend by limiting screen time or encouraging more time outdoors? Are there treatments that can help children and adolescents improve their vision? Which Vision Specialist Should You See? Eyes are complicated, and caring for vision problems has become increasingly specialized and technically sophisticated. As a result, ophthalmologists (eye doctors) now often treat just one part of the eye, such as the retina or the cornea. Some surgeons specialize in removing cataracts. Others, like Dr. Sharon Fekrat, are expert in retinal surgery. There are also pediatric ophthalmologists who treat children. In addition, some people need to consult a neuro-ophthalmologist or someone who specializes in inherited retinal degenerations, uveitis or ocular oncology. How can you determine which type of eye doctor you should see to address your particular problem most effectively? What Is in a Complete Eye Examination? Dr. Fekrat will describe the elements of a complete eye examination. Why is each one included? What further steps are needed if trouble is detected? This will give you an idea of how vision problems are assessed and where to turn for treatment. Managing Dry Eyes One of the most common complaints is dry eyes. This condition is uncomfortable as well as common, affecting up to half of adults in the US. What are the causes? Are there treatments? People often use eye drops to alleviate the discomfort. Which ones work best? What can a person do if they have severe dry eye problems and are referred to a dry eye specialist with an appointment months in advance? Is it dangerous to postpone dry eye care? What to Do About Blepharitis When the problem is more the eyelid than the eye itself, doctors call it blepharitis. One typical symptom is crust on the lids, which may feel itchy or scratchy. Some people find that applying warm compresses morning and evening is helpful. Others need medication. You may have seen ads for Xdemvy, which is aimed at reducing the population of Demodex mites living in the follicles of the eyelashes. Mites are not the only problem, however. Sometimes bacterial infections are the underlying cause of blepharitis. Rosacea and seborrheic dermatitis that affect skin elsewhere on the face may also show up with the same symptoms.  Topical ivermectin cream has been used off-label on the eyelid margins and may help reduce Demodex mites, but it is not an FDA-approved eye treatment and should only be used under an eye clinician's direction because it is not intended for instillation into the eye. How Will the Doctor Diagnose Glaucoma? Glaucoma is generally understood as a condition in which pressure inside the eye rises and damages the optic nerve. This disease can lead to vision loss. That's why intraocular pressure measurement should always be part of the eye exam. But this simple diagnostic technique alone may be incomplete. We'll ask Dr. Fekrat about additional approaches that might pick up normal-pressure glaucoma. How is it treated? Age-Related Macular Degeneration Deserves Treatment Another of the vision problems that can cause serious impairment is age-related macular degeneration. In this disorder, the central part of the retina, the macula, loses its ability to focus. Patients may notice that the central part of the vision is blurry, and it may be harder to see under low light conditions. Ophthalmologists now have a range of medications to inject to slow the progression of macular degeneration. Dr. Fekrat can describe the difference between “dry” and “wet” macular degeneration and the drugs used to treat them. What Other Vision Problems Are Troubling You? This is a chance to ask questions and get answers about vision problems from an expert. You can send email to radio@PeoplesPharmacy.com or call in your questions to 888-472-3366 between 7 and 8 am EDT on Saturday, June 20, 2026. This Week’s Guest Sharon Fekrat, MD, is a retina surgeon at the Duke Eye Center of the Duke Health Integrated Practice and vice chair of faculty affairs and the Robert Machemer MD Distinguished Professor of Ophthalmology at the Duke University School of Medicine. She is associate chief of staff at the Durham VA Healthcare System and past interim chief of surgery there. She is Director of Duke iMIND Research Group and Chief Editor of the book All About Your Eyes as well as the Digital Journal of Case Reports of Ophthalmology. Dr. Fekrat is past President of the NC Society of Eye Physicians and Surgeons. The People's Pharmacy is reader supported. When you buy through links in this post, we may earn a small affiliate commission (at no cost to you). Sharon Fekrat, MD, FASRS, Duke Eye Center Listen to the Podcast The podcast of this program will be available Monday, June 22, 2026, after broadcast on June 20. You can stream the show from this site and download the podcast for free. Download the mp3, or listen to the podcast on Apple Podcasts or Spotify.

Washington is one of 19 states that have received federal approval to enroll people in Medicaid before they leave jail or prison — a radical change in Medicaid policy that health care and law enforcement leaders believe will save lives. But this experiment in bringing Medicaid behind bars is now colliding with H.R. 1, the sweeping federal law that is forcing states to make major changes to Medicaid.Guest(s):Autumn Boylan, Deputy director, California Department of Health Care ServicesLauren Brinkley-Rubinstein, Professor, Population Health Sciences, Duke University School of MedicineCody CoughenourPete Croughan, Deputy secretary, Louisiana Department of HealthBruce Greenstein, Secretary, Louisiana Department of Health Tyron Nixon, Medicaid Reentry Transformation Implementation Manager, Washington State Health Care AuthorityEmma Sandoe, Medicaid director, OregonPenelope Sapp, Chief of corrections, Kitsap County Sheriff's OfficeMarc Stern, Former assistant secretary for health care at the Washington Department of CorrectionsTamara Vanover, Mental health specialist, Clallam County Sheriff's OfficeLearn more: Read the full reporting and explore additional resources on our website.Want more Tradeoffs? Join more than 5,500 readers who trust Tradeoffs for clear, deeply reported health policy insights. Sign up for our free weekly newsletter.Tradeoffs helps you cut through the noise with clear, deeply reported journalism on the forces driving health care's toughest choices — reporting you won't find anywhere else. If our work helps you stay informed, support it with a donation today.This episode was reported by Julie Wernau, edited by Dan Gorenstein and Ryan Levi, and mixed by Andrew Parrella and Cedric Wilson.The Tradeoffs theme song was composed by Ty Citerman. Additional music this episode from Blue Dot Sessions and Epidemic Sound.Special thanks to Gabrielle de la Gueronniere, Jody Rich and Kinda Serafi. Tradeoffs reporting for this story was supported, in part, by Arnold Ventures. Hosted on Acast. See acast.com/privacy for more information.

Prehospital blood is one of the hottest debates in trauma resuscitation — and the evidence just got a lot more interesting. In this episode, Drs. Patrick Georgoff and Ayman Ali sit down with Dr. Ed Barnard, UK defense professor of emergency medicine and author of the landmark SWIFT trial, and Dr. Juan De Chesney, trauma surgeon and pioneer in prehospital blood programs, to break down what we actually know about getting blood to patients before they hit the doors. The SWIFT trial — the largest prehospital whole blood RCT to date — found no superiority of whole blood over component therapy, but the story is far more nuanced than a negative headline suggests. From the logistics of carrying blood on a helicopter to the stark reality that only 1.8% of US ground EMS carries any blood products at all, this conversation exposes both the progress and the enormous gaps that remain. Hosts: Ayman Ali, MD: Ayman Ali is a Behind the Knife fellow and general surgery PGY-4 at Duke Hospital.  Patrick Georgoff, MD @georgoff: Patrick Georgoff is faculty in the Department of Surgery at the Duke University School of Medicine where he serves as an Associate Professor of Trauma, Acute, and Critical Care Surgery and Trauma Medical Director. He is a leading educator and creator for Behind the Knife, a premier digital education platform and podcast advancing surgical training through innovative, high-yield multimedia content. Juan Duchesne, MD: Juan Duchesne is a trauma surgeon and Professor of Surgery serving as the Trauma Medical Director and Division Chief at the University of Mississippi Medical Center. His pioneering contributions to the field—particularly in whole blood and balanced resuscitation practices—have been honored with numerous accolades.  Ed Barnard, PhD FRCEM FIMC RCSEd, @edbarn @DefProfEM: Ed Barnard is an emergency physician and UK Defence Professor of Emergency Medicine, RCEM/NIHR Associate Professor, and Affiliated Assistant Professor at the University of Cambridge. He has sub-specialty training in pre-hospital and academic emergency medicine and possesses extensive experience in trauma, anaesthesia, and critical care across both civilian and military settings. His contributions to the field have been honored with five national research awards and a PhD - undertaken with the US Army in San Antonio, TX. This episode was sponsored by Teleflex, a global provider of medical devices. Learn more at teleflex.com and at the Teleflex Trauma and Emergency Medicine LinkedIn page. Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Welcome to Season 3 of Ten to the Fifteenth: From Serendipity to Science, a 7 part mini-series in which we'll introduce you to the extraordinary world of brain stimulation. Huge shout outs to: Collin Price, Assistant Professor of Psychiatry and Behavioral Sciences at the Duke University School of Medicine, who was first author, champion, and all-around hero in bringing this season to life; Robert Scaramuccia, our amazing (and amazingly patient!) producer; to all of our guests this season; and to the rest of team NNCI for all of their hard work behind the scenes. In our first episode, Dr. Noah Philip takes us back to the beginning… This podcast is powered by ZenCast.fm

Spine Health Researcher, Clinician, and Professor, Dr. Christine Goertz shares her life's work in her new book Take Your Back Back. RESEARCH & HEALTH POLICY CAREER I'm Christine Goertz, D.C., Ph.D. I have spent 35 years working with multi-disciplinary teams to conduct research studies and implement best practices designed to optimize care for patients with low back pain. CURRENT ROLE I am a Professor in Musculoskeletal Research at the Duke Clinical Research Institute and Vice Chair for the Implementation of Spine Health Innovation in the Department of Orthopaedic Surgery at Duke University. I am also an Adjunct Professor in the Department of Epidemiology, College of Public Health at the University of Iowa.  WHERE IT ALL BEGAN I received my Doctor of Chiropractic (D.C.) degree from Northwestern Health Sciences University in 1991 and a Ph.D. in Health Services Research, Policy and Administration from the School of Public Health at the University of Minnesota in 1999. ACCOMPLISHMENTS I have extensive experience in the administration of Federal grants, both as a PI and as a program official at the National Institutes of Health (NIH). I have received nearly $45 million in federal funding, as the principal investigator or co-principal investigator, primarily from NIH and the Department of Defense. I have also co-authored more than 135 peer-reviewed scientific papers. MAKING A GLOBAL IMPACT I am honored to have delivered invited lectures, keynote talks, clinical grand rounds, and plenary presentations worldwide. Topics include "Research, Its Not Just for Scientists Anymore," "In Search of the Holy Grail in Low Back Pain Treatment or Anything that Works at All," and " Nonpharmacological Approaches to Pain Management." Venues include the Patient Centered Outcomes Research Institute Annual Meeting, Georgetown University, Duke University School of Medicine, the American Physical Therapy Association's Combined Sections Meeting, the American Chiropractic Association Summit, the World Federation of Chiropractic Research Congress, and the European Chiropractic Union.  Resources: Dr. Goertz's website The Back Pain Chronicles Pain Trainer Take Your Back Back The Cox 8 Table by Haven Medical Find a Back Doctor  

Building on the concepts introduced in the previous episode Rethinking the Design and Conduct of Kidney Trials, this episode explores how innovative ideas in nephrology research can be translated into practical trial strategies. Experts discuss novel approaches to trial design, evolving endpoint selection, and the importance of engaging patients, clinicians, regulators, and other stakeholders throughout the research process. Drawing on insights from the ISN Consensus Meeting on Changing Paradigms of Studies in CKD (Vancouver, Nov 22-23, 2024), the discussion highlights how more pragmatic and implementation-focused trials can help generate evidence that is meaningful for clinical practice and patient care worldwide. Speakers Adeera Levin Professor of Medicine, University of British Columbia, Canada, and Past-President of the International Society of Nephrology (ISN). Dr. Levin is a global leader in kidney health research, with extensive experience in chronic kidney disease (CKD) management, clinical trials, and international health system strengthening. David Wheeler Professor of Kidney Medicine at University College London, UK and Honorary Consultant Nephrologist at the Royal Free Hospital. His research focuses on the management of chronic kidney disease and the evaluation of therapies through large-scale clinical trials. He was co-principal investigator of the landmark DAPA-CKD trial and served as Co-Chair of KDIGO from 2012–2019.  Kevin Weinfurt Professor and Vice Chair of Faculty, Department of Population Health Sciences, Duke University School of Medicine, USA. Dr. Weinfurt is a behavioural scientist specializing in patient-reported outcomes (PROMs), ethical aspects of research participation, and improving the relevance of clinical trials to patients lived experiences. Hiddo J. Lambers Heerspink Professor of Clinical Trials and Personalized Medicine, University Medical Center Groningen, The Netherlands. Dr. Heerspink's work bridges pharmacology, nephrology, and precision medicine, focusing on optimizing kidney and cardiovascular outcomes through innovative clinical trial design and biomarker discovery. To read more, explore the related paper Changing Paradigms of Studies in Kidney Diseases published in Kidney International. 

In a cobranded episode between Oncology on the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Mitchell E. Horwitz, MD, highlighted key developments and ongoing initiatives related to allogeneic and cord blood transplantations among patients with different hematologic malignancies. The conversation touched upon the impact of omidubicel-onlv (Omisirge) on patient outcomes, current research on reducing the risk of graft-versus-host disease (GVHD) among transplantation recipients, and strategies for providing effective prophylaxis during treatment, among other topics. According to Horwitz, omidubicel has served as an “important graft source” for pediatric patients while improving cord blood transplantation for adults since its FDA approval in April 2023 for patients 12 years and older with hematologic malignancies. He also spoke to the importance of the FDA's approval of the agent in December 2025 for patients with severe aplastic anemia and no compatible donors following reduced intensity conditioning. Regarding those with severe aplastic anemia, he noted that omidubicel may considerably improve the feasibility of cord blood as a graft source for transplantation.Beyond these approvals, Horwitz described ongoing work dedicated to reducing the risk of GVHD following cord blood-derived transplantation, citing a pilot study that he and colleagues are conducting to determine the feasibility of adding a co-stimulatory blocking monoclonal antibody to help further limit this risk. Additionally, he emphasized surveilling for viruses like Epstein-Barr virus, HHV-6, and cytomegalovirus to mitigate the risks of delayed immune recovery following transplantation.“It's important to have all these [graft sources], whether it be cord blood, mismatched family members, mismatched unrelated donors, and matched siblings…to be made available [and] studied extensively,” Horwitz concluded. “We need to find what the best niche would be for each of these graft sources and make sure that [they] are utilized at the various institutions. The nuances, such as infection prophylaxis or infection monitoring, [should become] familiar to the transplant centers. By doing that, we can continue this trend of having a graft source for everyone and improving outcomes.”Horwitz is a professor of Medicine, Hematologic Malignancies and Cellular Therapy at Duke University School of Medicine and cellular therapy and stem cell specialist at Duke Cancer Institute.References FDA approves cell therapy for patients with blood cancers to reduce risk of infection following stem cell transplantation. News release. FDA. April 17, 2023. Accessed May 20, 2026. bit.ly/3UEO3kp FDA approves first cellular therapy to treat patients with severe aplastic anemia. News release. FDA. December 8, 2025. Accessed May 20, 2026. https://tinyurl.com/yuu377yt

As we continue to look ahead to Summer Programs, we are introducing you to a new friend of Regent, Dr. Warren Kinghorn, psychiatrist and theologian at Duke University. In this sensitive and insightful conversation, Warren reflects on his many years practising medicine as a Christian psychiatrist. He considers the intersection of psychiatry, theology, and human experience, emphasizing the importance of understanding people as whole persons on a journey rather than machines or clusters of symptoms.  He points us to the reality of human interdependence as a gift, and our common humanity as wayfarers, persons on a journey, seeking to discern what we need in the particularities of our lives in community with others. Warren will be joining us at Regent from July 6-10 to teach “Christian Faith and Mental Healthcare.” We hope to see you here!(TW) Warren discusses difficult issues, such as suicidality and euthanasia, as well as other mental health challenges.Warren's BioDr. Warren Kinghorn is Professor of Psychiatry at Duke University School of Medicine, Esther Colliflower Professor of the Practice of Pastoral and Moral Theology, and co-director of the Theology, Medicine, and Culture Initiative at Duke Divinity School, and a staff psychiatrist at the Durham VA Medical Center. He is the author of Wayfaring: A Christian Approach to Mental Health Care (Eerdmans, 2024) and co-author with Abraham Nussbaum of Prescribing Together: A Relational Guide to Psychopharmacology (American Psychiatric Association Publishing, 2021). He's teaching this summer: Christian Faith and Mental Healthcare from July 6-10.  Referenced ContentDo Not Harm Yourself, For We Are All Here - Christianity Today article (May 2025)Regent College PodcastThanks for listening. Please like, rate and review us on your podcast platform of choice and share this episode with a friend. Follow Us on Social MediaFacebookInstagramYoutubeKeep in TouchRegent CollegeSummer ProgramsRegent College Newsletter

Can an algorithm actually give you your life back? A recent Stanford paper revealed that using large language models at home yields massive efficiency gains—up to 176%. For busy surgeons drowning in clinical duties and administrative bloat, every reclaimed second is priceless.In this episode of Behind the Knife, Ayman and Patrick sit down with Christian Péan—an orthopedic trauma surgeon, Duke's Executive Director of AI and IT Innovation, and the Founder/CEO of RevelAi Health. He's also a Core faculty member at the Duke-Margolis Institute for Health Policy. Dr. Péan breaks down how naturally skeptical surgeons can adopt AI to save time, shares his granular daily workflow, and discusses his mission to cure physician burnout through tech. Whether you are a tech enthusiast or a total skeptic, this episode gives you the practical playbook for integrating AI into your surgical career today.Hosts:- Ayman Ali, MDAyman Ali is a PGY-4 at Duke Hospital and current Behind the Knife fellow.- Patrick Georgoff, MD @georgoffPatrick Georgoff is faculty in the Department of Surgery at the Duke University School of Medicine where he serves as an Associate Professor of Trauma, Acute, and Critical Care Surgery and Trauma Medical Director. He is a leading educator and creator for Behind the Knife, a premier digital education platform and podcast advancing surgical training through innovative, high-yield multimedia content.- Christian Péan, MD @DrChristianPeanChristian Péan is faculty in the Department of Orthopaedic Surgery at the Duke University School of Medicine where he serves as Executive Director of AI and IT Innovation. He is the Founder and CEO of RevelAi Health, a health technology company advancing the transition to value-based care in musculoskeletal health with conversational AI. He is also author of the popular substack Techy Surgeon.  https://www.revelaihealth.com/https://techysurgeon.substack.com/Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

  In March of 2026, the International Olympic Committee released a new policy on the Protection of the Female (Women's) Category in Olympic Sports. This new policy is applicable to the 2028 Olympic Games to be hosted in Los Angeles and onward and is not being applied retroactively or to any grassroots or recreational sports programs.  But what does this new policy address and how what should we think about this. I have a longtime friend and mentor as my guest today who will help us work through this topic.    Connect with The Host! Subscribe to This Podcast Now!     The ultimate success for every podcaster – is FEEDBACK! Be sure to take just a few minutes to tell the hosts of this podcast what YOU think over at Apple Podcasts! It takes only a few minutes but helps the hosts of this program pave the way to future greatness! Not an Apple Podcasts user? No problem! Be sure to check out any of the other many growing podcast directories online to find this and many other podcasts via The Podcaster Matrix!     Housekeeping -- Get the whole story about Dr. Mark and his launch into this program, by listing to his "101" episode that'll get you educated, caught up and in tune with the Doctor that's in the podcast house! Listen Now! -- Interested in being a Guest on The Pediatric Sports Medicine Podcast? Connect with Mark today!   Links from this Episode: -- Dr. Mark Halstead: On the Web -- On X  -- David Allen, MD Profile https://www.uwhealth.org/providers/david-b-allen-md Publications/Milestones https://www.pediatrics.wisc.edu/staff/allen-david/ IOC New 2026 Policy on Protection of Female (Women) Category in Olympic Sports https://www.olympics.com/ioc/news/international-olympic-committee-announces-new-policy-on-the-protection-of-the-female-women-s-category-in-olympic-sport Rupert JL. Genitals to genes: the history and biology of gender verification in the Olympics. Can Bull Med Hist. 2011;28(2):339-65. doi: 10.3138/cbmh.28.2.339. PMID: 22164600. https://pubmed.ncbi.nlm.nih.gov/22164600/   Calls to the Audience Inside this Episode: -- Be sure to interact with the host, send detailed feedback via our customized form and connect via ALL of our social media platforms! Do that over here now! -- Interested in being a guest inside The Pediatric Sports Medicine Podcast with Dr. Mark? Tell us now! -- Ready to share your business, organization or efforts message with Dr. Mark's focused audience? Let's have a chat! -- Do you have feedback you'd like to share with Dr. Mark from this episode? Share YOUR perspective!   Be an Advertiser/Sponsor for This Program!     Tell Us What You Think! Feedback is the cornerstone and engine of all great podcast. Be sure to chime in with your thoughts, perspective sand more.  Share your insight and experiences with Dr. Mark by clicking here!   The Host of this Program: Mark Halstead:  Dr. Mark Halstead received his medical degree from the University of Wisconsin Medical School. He stayed at the University of Wisconsin for his pediatric residency, followed by a year as the chief resident. Following residency, he completed a pediatric and adult sports medicine fellowship at Vanderbilt University. He has been an elected member to the American Academy of Pediatrics (AAP) Council on Sports Medicine and Fitness and the Board of Directors of the American Medical Society for Sports Medicine (AMSSM). He has served as a team physician or medical consultant to numerous high schools, Vanderbilt University, Belmont University, Washington University, St. Louis Cardinals, St. Louis Blues, St. Louis Athletica, and St. Louis Rams. He serves and has served on many local, regional and national committees as an advisor for sports medicine and concussions. Dr. Halstead is a national recognized expert in sport-related concussions and pediatric sports medicine. — Dr. Mark Halstead on Facebook — Dr. Mark Halstead on LinkedIn — Dr. Mark Halstead on X — Learn Why The Pediatric Sports Medicine Podcast Exists...   The Guest Featured Inside this Program: David Allen David B. Allen, MD, is Professor of Pediatrics at the University of Wisconsin School of Medicine and Public Health, and Head of Endocrinology and Diabetes and Director of the Endocrinology and Diabetes Fellowship Program at the University of Wisconsin American Family Children's Hospital in Madison.  He graduated from Stanford University with honors in humanities and biology, obtained his MD degree from Duke University School of Medicine, and completed pediatric residency, chief residency, and a fellowship training at the University of Wisconsin. He is the recipient of numerous awards for excellence in education, clinical care, and academic leadership, most notably the ACGME Parker Palmer “Courage to Teach” national award, the University of Wisconsin Presidential Physician Leadership Award, the Wisconsin Medical Alumni Association Career Citation Award, the University of Wisconsin Clinical Educator Award, and the Judson Van Wyk Prize for outstanding career achievement given by the Pediatric Endocrine Society. Dr. Allen served as Director of the UW Pediatric Residency Program from 1993-2007 and as Program Director of the UW Pediatric Endocrinology and Diabetes Fellowship since 2003.  On the national level, Dr. Allen was elected Director (2000-2003) and then President (2010-2011) of the Pediatric Endocrine Society.  He served as Chair of the Wisconsin Endocrine Newborn Screening Committee from 1991-2015, and as member of the American Board of Pediatrics sub-board for Pediatric Endocrinology 2010-2015.  He is an editorial reviewer for numerous peer-reviewed journals, served as editorial board member for the Journal of Clinical Endocrinology and Metabolism and Associate Editor for the International Journal of Pediatric Endocrinology.  On the international level, Dr. Allen was selected to Chair the Organizing Committee for and then serve as President of the 2017 10th International Meeting of Pediatric Endocrinology. His research interests have included innovative use of human growth hormone to restore normal growth and increase physical function in children with glucocorticoid-induced growth suppression and with Prader-Willi syndrome. He has also led studies of childhood adipose organ development and dysfunction, improving fitness and insulin sensitivity to prevent diabetes onset in children, improving newborn screening programs for endocrine disorders, and preventing and assessing systemic effects of inhaled corticosteroids.  Throughout his career, Dr. Allen has also spoken and published extensively about issues of ethics and cost-effectiveness in the treatment of disorders of childhood growth.  He has written more than 240 articles, letters, monographs, and book chapters, edited 4 textbooks, and has presented at more than 180 regional, national, and international meetings. Dr. Allen's personal interests include improvisational jazz piano and providing philanthropic music for local charities and missions.  He is an avid cyclist, skier, and runner (two-time US Olympic Marathon trials qualifier with a PR of 2 hours 17 minutes) and most importantly, a doting grandfather.

In this special Complex Care Journal Club podcast episode, co-hosts Drs. Emily Goodwin, Kristie Malik, and Kathleen Huth interview presenters of posters and oral abstracts relevant to the care of children with medical complexity at the Pediatric Academic Societies (PAS) 2026 annual meeting, as well as at a pre-PAS event focused on home- and community-based care and training in complex care. Speakers describe their key findings, messages for care teams including patients and families, and opportunities to translate their findings into practice.‌ SPEAKERS Flor Arellano, MPH Clinical Research Coordinator, University of California, Los Angeles Jennifer Arnold, MD, MSc Medical Director, Skeletal Health, Boston Children's Hospital Ryan Brewster, MD Neonatal- Perinatal Medicine Fellow, Stanford University School of Medicine Meg Comeau, MHA Senior Project Director, Center for Innovation in Social Work & Health, Boston University School of Social Work John Greenwood, PT Executive Director for Physical Therapy, Occupational Therapy and Rehabilitation Services, Boston Children's Hospital Elaine Lin, MD Complex Care Pediatrician, Boston Children's Hospital Michelle Macy, MD, MS Professor of Pediatrics, Northwestern University Feinberg School of Medicine Scientific Director, Community, Population Health, and Outcomes, Research and Evaluation Center, Ann & Robert H. Lurie Children's Hospital of Chicago Ashley Nmoh, BA Medical Student, Duke University School of Medicine Jennifer Peralta, MD, MSHPN Assistant Clinical Professor, University of California, Los Angeles Nora Renthal, MD, PhD Assistant Professor of Pediatric Endocrinology, Boston Children's Hospital Erin Ward, MEd Patient Engagement Consultant, Complex Care Service, Boston Children's Hospital HOSTS Emily J. Goodwin, MD Clinical Associate Professor of Pediatrics, University of Missouri Kansas City School of Medicine Pediatrician, General Academic Pediatrics Beacon Program, Children's Mercy Kansas City Kristina Malik, MD Assistant Professor of Pediatrics, University of Colorado School of Medicine Medical Director, KidStreet Pediatrician, Special Care Clinic, Children's Hospital Colorado Kathleen Huth, MD, MMSc Pediatrician, Complex Care Service, Division of General Pediatrics, Boston Children's Hospital Assistant Professor of Pediatrics, Harvard Medical School DATE Initial publication date: May 11, 2026. ARTICLES REFERENCED - Brewster RC, Kats DJ, Elborki M, Chilukuri N, Ray M, Shaar N, Hron J, Khan A. Clinical Outcomes of Postedited Artificial Intelligence Translation for Discharge Instructions. Hosp Pediatr. 2026 Apr 10:e2025008986. doi: 10.1542/hpeds.2025-008986. Epub ahead of print. PMID: 41956490. - FamilyCIRCLE. University of Wisconsin–Madison, Department of Pediatrics. Accessed May 4, 2026. https://familycircle.pediatrics.wisc.edu/ - Pediatric Academic Societies. Online program guide. Accessed May 4, 2026. https://2026.pas-meeting.org/ - Pediatric Academic Societies. Who we are. Accessed May 4, 2026. https://www.pas-meeting.org/about/ - Pediatric Academic Societies. Academic Pediatric Association (APA) awards. Accessed May 4, 2026. https://www.pas-meeting.org/2026-awards-apa/‌ TRANSCRIPT https://cdn.bfldr.com/D6LGWP8S/as/k7qqm93qqpqgb5k3jw4f3w2t/PAS_2026_conference_transcript_5-8-26‌ Clinicians across healthcare professions, advocates, researchers, and patients/families are all encouraged to engage and provide feedback! You can recommend an article for discussion using this form: https://forms.gle/Bdxb86Sw5qq1uFhW6. CITATION Goodwin EJ, Malik K, Arellano F, Arnold J, Brewster R, Comeau M, Greenwood J, Lin E, Macy M, Nmoh A, Peralta J, Renthal N, Ward E, Huth K. Practice-Changing Research in Complex Care at the Pediatric Academic Societies 2026 Annual Meeting. 05/2026. OPENPediatrics. Online Podcast. https://soundcloud.com/openpediatrics/practice-changing-research-in-complex-care-pediatric-academic-societies-2026.

Health Affairs Publishing's Jeff Byers welcomes Duke University School of Medicine's Mike Pignone to the pod to explore the new cholesterol screening guidelines, how evolving screening and treatment guidelines (including colon cancer and breast cancer screening guidelines) influence care, and the broader cost implications for the health system. Join Health Affairs Publishing on May 13 for an exclusive Insider virtual event exploring individual coverage health reimbursement arrangements (ICHRAs) with Urban Institute's Jason Levitis.Related Articles:Generic cholesterol drugs save Medicare billions of dollars, study finds (UT Southwestern Medical Center)Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol–Lowering Therapies Among Medicare Beneficiaries (JAMA)A cholesterol test you've never heard of is now recommended to prevent heart disease (NPR)ACC/American Heart Association Issue Updated Guideline for Managing Lipids, Cholesterol (American Heart Association)Sign up for Health Affairs' free newsletter to catch up on our new articles, podcasts, and events.

Season FIVE Episode TWELVE of the Your Story Our Fight® podcast welcomes AlexAndriA G. Porter. AlexAndriA is a Master of Nursing student at the Duke University School of Nursing, published scholar, and multidisciplinary leader whose work bridges healthcare, advocacy, and the arts. She serves as the 2025 Cohort Representative, Student Liaison for the Clinical Resource Team, and President of Nurses Amplifying Voices (NAV), advancing equity and student engagement in nursing. With a background in psychology, business, civil rights advocacy, and clinical care, she brings both analytical rigor and compassionate leadership to her work. Despite being diagnosed with a lupus adjacent disorder, she is trained in acting, musical theater, and dance—including at the Joffrey Ballet School—she values storytelling and creative expression as powerful tools for connection, healing, and amplifying voices.

Can identifying the right patients and the right endpoints transform how we test new osteoarthritis treatments? On this week's episode of Joint Action, we unpack what the FNIH Biomarkers Consortium has learned so far, and how their latest phase aims to deliver biomarkers that can make disease-modifying OA drug trials smaller, faster, and more likely to succeed.Dr. Virginia Byers Kraus is a Professor of Medicine, Pathology, and Orthopaedic Surgery at Duke University School of Medicine. A rheumatologist and translational scientist, her research focuses on osteoarthritis and biomarker development as part of the international FNIH Biomarkers Consortium.Peter G. Mesenbrink, Ph.D., is Executive Director of Biostatistics at Novartis and industry co-chair of the FNIH Biomarkers Consortium. With expertise in adaptive trial design, surrogate endpoint development, and data sharing policy, he is a frequent collaborator across industry, regulatory, and academic communities.Dr. Jamie Collins is a biostatistician at Brigham and Women's Hospital and Associate Professor of Orthopaedic Surgery at Harvard Medical School. As lead statistician for the FNIH OA Biomarkers Consortium, her research focuses on strengthening osteoarthritis clinical trials through innovative trial design and prognostic enrichment.RESOURCESFNIH: Treatment Response Biomarkers for Disease Modifying Osteoarthritis Drugs (DMOADs)CONNECT WITH USNaia Health: https://www.naiahealth.com.au/st-leonards-hubJoin one of our trials https://www.osteoarthritisresearch.com.au/current-trialsInstagram: @ProfDavidHunterTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcastIf you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! Hosted on Acast. See acast.com/privacy for more information.

In this episode, we explore the grueling realities of the general surgery preliminary year—a high-stakes, one-year audition for surgical trainees operating without a safety net. We sit down with a program director, a former IMG prelim turned attending, and a recently successful SOAP applicant to uncover exactly what it takes to survive the scramble and excel clinically. Listen in to learn actionable strategies for navigating hospital expectations, securing vital mentorship, and ultimately turning your preliminary position into a secured categorical spot.Hosts:Ayman Ali, MDDr. Ayman Ali is a Behind the Knife fellow and general surgery PGY-4 at Duke Hospital. Kevin Naresh Shah, MDDr. Kevin Shah is an Assistant Professor of Hepatobiliary Surgery at the Duke University School of Medicine and Program Director of General Surgery. Katharine Louise Jackson, MBBSDr. Louise Jackson is an Assistant Professor of Colon and Rectal Surgery at the Duke University School of Medicine and the Medical Student Clerkship Director. Rafael Felix Tiongco, MDDr. Rafael Tiongco is a first-year resident at Penn State College of Medicine.Sponsor Disclaimer: Visit goremedical.com/btkpod to learn more about GORE® SYNECOR Biomaterial, including supporting references and disclaimers for the presented content.  Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only ***Fellowship Application Link: https://forms.gle/QSUrR2GWHDZ1MmWC6Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Welcome to Fertility and Sterility Roundtable, hosted by Dr. Emily Barnard and Dr. Ben Peipert! Each week, we will host a discussion with the authors of "Views and Reviews" and "Fertile Battle" articles published in a recent issue of Fertility and Sterility.  Today, we will be discussing the Fertile Battle from the February issue of Fertility and Sterility which is entitled "Should you do ultrasound monitoring and trigger for intrauterine insemination cycles? We are joined by two of the authors, Dr. Cassie Hobbs who will be taking the "pro" side in favor of ultrasound monitoring, and Dr. Lindsay Hartup, who will be arguing to do away with ultrasound monitoring.  Dr. Cassie Hobbs is a second-year Reproductive Endocrinology and Infertility fellow at the University of Pennsylvania. She completed her OB/GYN residency training at Brown University and received her medical degree from Duke University School of Medicine. She is passionate about examining disparities that exist in reproductive medicine and taking steps to make family building a more equitable process for all.  Dr. Lindsay Hartup is a Reproductive Endocrinology and Infertility fellow at Brigham and Women's Hospital. She completed medical school and Obstetrics and Gynecology residency at the University of Texas Health San Antonio. Her research interests are fertility preservation/oncofertility, assisted reproductive technology, and chronic endometritis. Read the Fertile Battle from Volume 125, Issue 2 p228-233 in the February 2026 issue View Fertility and Sterility at https://www.fertstert.org/  

In this episode, Dr. Christian Péan, CEO and Co Founder of Revel Ai Health and practicing orthopedic trauma surgeon at Duke University School of Medicine, discusses how AI is redefining surgical readiness in ambulatory surgery centers. He explores scalable use cases in patient engagement, quality reporting, interoperability, and how ASC leaders can prepare their data, workflows, and culture for safe AI adoption. This episode is sponsored by Revel Ai.

In this episode, Dr. Christian Péan, CEO and Co Founder of Revel Ai Health and practicing orthopedic trauma surgeon at Duke University School of Medicine, discusses how AI is redefining surgical readiness in ambulatory surgery centers. He explores scalable use cases in patient engagement, quality reporting, interoperability, and how ASC leaders can prepare their data, workflows, and culture for safe AI adoption. This episode is sponsored by Revel Ai.

Who determines what 'good' Compliance actually looks like?  The obvious answer is regulators (and in some jurisdictions) prosecutors. But what if it were the regulated Firms themselves?  That's the idea behind purpose-driven compliance, which I'm exploring on this episode.Episode Summary To explore this, I'm joined by Veronica Root Martinez, Professor of Law at Duke University School of Law, to explore a deceptively simple but unsettling idea: 100% compliance is impossible. While we often behave as though perfect compliance is the goal — and in some safety-critical domains it must be — most organisational compliance involves humans. And humans make mistakes. Things get missed. Context changes. Stuff goes wrong.So if perfection isn't realistic, the real question becomes: how do organisations decide what really matters? The traditional answer has been to look outward — to regulators, enforcement authorities, and in some jurisdictions (particularly the US), prosecutors. Their priorities, expressed through sentencing guidelines, enforcement actions, and settlements, end up defining what “good” compliance looks like. Veronica challenges that logic. She argues that this gets things the wrong way round. Instead of letting enforcement priorities dictate behaviour, she makes the case for purpose-driven compliance — where organisations set their own priorities based on their purpose, values, and actual risks, rather than chasing shifting regulatory expectations. Along the way, the conversation explores culture, human judgment, psychological safety, technology, experimentation, and why “best practice” can sometimes make things worse rather than better. This episode is for anyone who writes rules, enforces them — or simply has to live under them.Guest BiographyVeronica Root Martinez is a Professor of Law at Duke University School of Law, where she researches corporate compliance, ethics, and organisational culture. Her work on purpose-driven compliance challenges enforcement-led models and explores how organisations can set priorities based on their own purpose, values, and risks.Before entering academia, Veronica practised as an associate at a large law firm in Washington, DC, where she worked on regulatory and white-collar matters — experience that strongly informs the practical orientation of her research.LinksProfessor Veronica Root Martinez – Faculty Profilehttps://law.duke.edu/fac/martinezVeronica on LinkedInhttps://www.linkedin.com/in/veronica-root-martinez/Purpose-Driven Compliance (paper discussed in the episode)https://papers.ssrn.com/sol3/papers.cfm?abstract_id=6078766AI-Generated Timestamped Summary00:00 – 02:00 | “Because they said so”Christian reframes compliance as a universal human experience — not just a professional discipline — and introduces the problem of rules justified solely by regulatory expectation.02:00 – 05:30 | Why 100% compliance is impossibleVeronica explains why modern organisations cannot realistically achieve perfect compliance when humans are involved — and why pretending otherwise creates problems.05:30 – 10:30 | Tolerated misconduct and cultural driftHow allowing “small” rule-breaking can escalate into bigger issues, drawing on behavioural ethics and real-world corporate failures. 10:30 – 14:30 | Risk, prioritisation, and what really mattersA discussion of risk-based thinking, irrecoverable vs recoverable errors, and why organisations — not regulators — are best placed to set priorities. 14:30 – 18:30 | Enforcement swings and resilienceWhy compliance programmes built around enforcement trends are fragile, expensive, and reactive — and how purpose-driven approaches create stability. 18:30 – 23:30 | Innovation, uncertainty, and guardrailsWhy regulators are always behind innovation — and how values-based guardrails help employees make decisions in uncharted territory.23:30 – 30:30 | Technology, AI, and the human in the loopThe limits of automation, the danger of over-reliance on tech, and why human judgment remains essential.30:30 – 36:30 | Rules, loopholes, and malicious complianceHow overly detailed rulebooks create loopholes — and why purpose and principles offer a better basis for accountability.36:30 – 40:30 | The Costco exampleA powerful illustration of simplicity: four ethical principles that employees can actually understand and use.40:30 – 45:30 | Training, regulators, and unintended consequencesWhy blanket training requirements often miss the mark — and how enforcement agreements can accidentally undermine effectiveness.45:30 – 52:30 | Measuring culture and compliance effectivenessMoving beyond counting inputs to assessing outputs, including psychological safety, Speak Up systems, and cultural indicators.52:30 – 57:30 | Experimentation and learningWhy failed interventions aren't failure — they're information — and why compliance should be treated as an evolving experiment.57:30 – End | Reclaiming responsibilityA closing reflection on extrinsic motivation, “because I said so,” and why purpose-driven compliance offers a more human, defensible, and sustainable way forward.

Tobias Straube, MD, is an Assistant Professor of Pediatrics in the Division of Critical Care Medicine at Duke University School of Medicine, where he has served since joining the faculty in July 2021. He completed his pediatric residency and critical care fellowship at Duke University Hospital following earning his medical degree from McGovern Medical School at UTHealth. COI disclosure: Dr. Straube is the Chief Medical Officer of VQ Biomedical working to develop a minimally-invasive oxygenator catheter. This work is unrelated to this content discussed in today's episode. Learning Objective:By the end of this podcast, listeners should be able to describe an evidence-based and expert-guided clinical approach to the recognition and management of exertional heat stroke in critically-ill children.Questions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the showHow to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. You can also check out our website at http://www.pedscrit.com. Thank you for listening to this episode of PedsCrit!

When Bernie Lewinsky was a young radiotherapy resident, he studied under some of the most storied names in the field. Now, over fifty years later, he marvels at how much radiation oncology has changed. “You've gone from a betatron, cobalt and radium needles, and treating AP one day and PA the next, to probably treating on some sort of amazing [technology like a] TrueBeam or Elekta,” said Stacy Wentworth, a radiation oncologist at Duke University School of Medicine, who hosted this episode of the Cancer History Project Podcast.Lewinsky was one of the co-founders of the Endocurietherapy Society, which now exists as the American Brachytherapy Society. He has also helped develop the first group of freestanding radiation therapy clinics in Los Angeles, CA. Throughout the years—whether during his rotation at the Royal Marsden Hospital in London during residency or participating in tumor boards at UCLA—he has been part of many fervent debates with radiotherapy legends, arguing over whether Hodgkin's lymphoma spreads up or down the body, and the legitimacy of Intensity-Modulated Radiation Therapy in the early days. “Now it's so much more accurate, so much different and so precise,” Lewinsky said. “When you start talking about blocking the nodes in the heart to stop arrhythmias, we're very specific.”Lewinsky brings a treasure trove of artifacts to the interview—written orders of radium needles from 1948, an attachment that connected to an orthovoltage machine, a Mick applicator, and even a Bunsen burner. He plans to send some of these relics to the archives at ASTRO or the American College of Radiology. Beyond his practice of medicine, Lewinsky has also brought healing to his patients through his landscape photography. Some of his first photos captured an active volcano in El Salvador, where he grew up. Prints of some of his photographs can be found on the covers of academic journals and on the walls of his office. He distinctly remembers one patient, whose attention drifted off during an office visit. Lewinsky says the patient was struck by a photo of cherry blossoms he took in London.  “I said, ‘Wait a minute, what is it about that picture that's got you mesmerized?' and he says, ‘I remember when I was a little kid, my dad would take us cherry-picking. I sure wish my dad was here right now,” Lewinsky said. “It became my observation that there is a healing aspect to nature photography and putting it in the office when a patient is under tremendous stress, it not only calms the patient, but it brings back memories that they cherish.”A transcript of this interview is available at https://cancerhistoryproject.com/article/bernie-lewinsky-podcast/ 

When it comes to “bad” cholesterol, most cardiologists say lower is better. But what's the best way to get that number down? Can diet and exercise alone do the job?Cardiologists Kiran Musunuru and Neha Pagidipati join Host Ira Flatow for a look at the latest in cholesterol-lowering treatments, including CRISPR technology that could turn off cholesterol-making genes for life. How does it work, and is it safe?Guests:Dr. Kiran Musunuru is the scientific director of the Center for Inherited Cardiovascular Disease at the Perelman School of Medicine at the University of Pennsylvania.Dr. Neha Pagidipati is the director of the Cardiometabolic Prevention Clinic at the Duke University School of Medicine in Durham, NC.Transcripts for each episode are available within 1-3 days at sciencefriday.com.  Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Guest: John H. Strickler, MD The treatment landscape for HER2-positive gastroesophageal cancer is rapidly evolving, with zanidatamab emerging as a new option following years of limited progress beyond trastuzumab. Dr. John Strickler joins us to share insights on how recent FDA approvals and novel agents are transforming outcomes in this complex disease setting. Dr. Strickler is a Professor of Medicine in the Division of Medical Oncology at Duke University School of Medicine and Co-Leader for the Precision Cancer Medicine and Investigational Therapeutics Program at the Duke Cancer Institute.

Improving outcomes for those with the deadliest cancers is ongoing. Trudy G. Oliver, professor in the department of pharmacology and cancer biology at the Duke University School of Medicine, examines a possible new step forward. Trudy G. Oliver, PhD, is a Professor of Pharmacology & Cancer Biology at Duke University and a Duke Science & […]

This week Dr. Greg talks with Dr. Jocelyn Wittstein, associate professor of orthopaedic surgery at Duke University School of Medicine, about how important maintaining bone health is for all women. Dr. Wittstein recently conducted a coffee talk on this very subject for the Active Girls Healthy Women group at UK.

Welcome to OncLive On Air®! OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today's episode, we had the pleasure of speaking with Harry P. Erba, MD, PhD, about the FDA approval of ziftomenib (Komzifti) for the treatment of adult patients with relapsed/refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. Dr Erba is a professor of medicine in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine at the Duke University School of Medicine, as well as director of the Leukemia Program and director of Phase I Development in Hematologic Malignancies. He is also a member of the Duke Cancer Institute in Durham, North Carolina. In our exclusive interview, Dr Erba discussed the significance of this approval, key efficacy and safety findings from the pivotal phase 1/2 KOMET-001 trial (NCT04067336), and the role ziftomenib may play throughout the evolution of the AML treatment paradigm. _____ That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters. OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn. If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us! Thanks again for listening to OncLive On Air. *OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn. This content is a production of OncLive; this OncLive On Air podcast is supported by funding, however, content is produced and independently developed by OncLive.

Clinical trial design in nephrology is evolving. In this episode, leading experts explore why a paradigm shift is needed from traditional biomarkers to patient-centered outcomes and practical strategies for advancing trial implementation. This conversation draws on insights from the ISN Consensus Meeting on Changing Paradigms of Studies in CKD (Vancouver, Nov 22-23, 2024) where clinicians, trialists, patient partners, regulators and industry scientists came together to rethink trial endpoints, outcomes and designs. Together, they discuss how reimagining kidney trials can generate more relevant, equitable, and actionable evidence for better kidney care worldwide. ParticipantsAdeera Levin Professor of Medicine, University of British Columbia, Canada, and Past-President of the International Society of Nephrology (ISN). Dr. Levin is a global leader in kidney health research, with extensive experience in chronic kidney disease (CKD) management, clinical trials, and international health system strengthening. Jennifer Lees Senior Clinical Lecturer and Honorary Consultant Nephrologist at the University of Glasgow, UK. Dr. Lees' research focuses on improving patient outcomes in kidney disease through better trial design, biomarker evaluation, and translational approaches linking research to clinical care. Kevin Weinfurt Professor and Vice Chair of Faculty, Department of Population Health Sciences, Duke University School of Medicine, USA. Dr. Weinfurt is a behavioural scientist specializing in patient-reported outcomes (PROMs), ethical aspects of research participation, and improving the relevance of clinical trials to patients lived experiences. Hiddo J. Lambers Heerspink Professor of Clinical Trials and Personalized Medicine, University Medical Center Groningen, The Netherlands. Dr. Heerspink's work bridges pharmacology, nephrology, and precision medicine, focusing on optimizing kidney and cardiovascular outcomes through innovative clinical trial design and biomarker discovery. To read more, explore the related paper Changing Paradigms of Studies in Kidney Diseases published in Kidney International.

On this week's episode, Dan is joined by Timothy Meyer, Professor in International Business Law at Duke University School of Law, to discuss Supreme Court arguments on tariffs. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Two-time Emmy and three-time NAACP Image Award-winning television Executive Producer Rushion McDonald interviewed Dr. Schenta D. Randolph.

Two-time Emmy and three-time NAACP Image Award-winning television Executive Producer Rushion McDonald interviewed Dr. Schenta D. Randolph.

Two-time Emmy and three-time NAACP Image Award-winning television Executive Producer Rushion McDonald interviewed Dr. Schenta D. Randolph.

On this edition of The Mark White Show, we're shining a light on the often-overlooked heroes in prostate cancer care, the caregivers. A new national survey reveals that 85% of caregivers attend medical appointments with their loved one and are four times more likely to notice treatment side effects than the patients themselves. Joining me are Dr. Daniel George, Medical Oncologist and Professor at Duke University School of Medicine, and Gina Carithers, President of the Prostate Cancer Foundation. Together, we discuss what this survey uncovers about the day-to-day realities of caregiving, how families can better navigate this journey, and the vital importance of supporting those who give so much of themselves in the process.

Does everything hurt and you feel like you're in a ‘down hill from here' phase of life? Nope. You need this week's show if those thoughts have been creeping in!Enter Dr Jocelyn Wittstein, M.D., an associate professor of orthopaedic surgery at Duke University School of Medicine. She has been in practice since 2010 and is fellowship trained in sports medicine. She's a clinician researcher with NIH funded research in ACL injury, sex differences in ACL injury, and cartilage health and she also studies the intersection of women's health and musculoskeletal health. I grilled her for as much as we could get through in an hour for us. We unpack:

Many medical trainees are driven to medicine by their moral or religious principles — only to find that they are expected to check their principles at the patient's door. When this happens, physicians and patients may lose the opportunity for deeper, more healing relationships.Our guest on this episode is Dr. Farr Curlin, a hospitalist and palliative care physician at Duke University School of Medicine. Dr. Curlin holds joint appointments in the Trent Center for Bioethics, Humanities & History of Medicine and Duke Divinity School, where he studies the intersection of medicine, ethics, and religion. From a young age, Dr. Curlin was intrigued by the moral dimensions of medicine. As a medical trainee, he began to study how the religious backgrounds of physicians inform their practice. He is the co-author of The Way of Medicine, in which he challenges the modern “provider of services” model and calls for a recovery of medicine's spiritual foundations as a healing profession. Now, at Duke Divinity School, he spends significant time helping physicians re-center their practice around the question: “What is Good?” Over the course of our conversation, we discuss attitudes toward religion in the medical profession and how many medical professionals worry that being openly religious may make them seem retrograde — or worse. We explore striking the balance between offering physician wisdom while respecting patient autonomy, consider whether the project of medicine makes sense when viewed through the lens of secular humanism, and reflect on how the physician attributes of humility and respect enable physicians to productively bring their full selves to the bedside, all while practicing medicine within a morally pluralistic society.In this episode, you'll hear about: 2:48 - Dr. Curlin's path to medicine and what drew him to a career at the intersection of religion and medicine 19:30 - Dr. Curlin's thoughts on why doctors often feel they cannot be openly religious35:45 - How Dr. Curlin would change medical training to create a deeper focus on personal commitments and moral conviction 41:15 - Exploring the limitations of artificial agnosticism at the patient's bedside51:50 - How fostering a spiritual connection to the work of healing can mitigate burnoutVisit our website www.TheDoctorsArt.com where you can find transcripts of all episodes.If you enjoyed this episode, please subscribe, rate, and review our show, available for free on Spotify, Apple Podcasts, or wherever you get your podcasts. If you know of a doctor, patient, or anyone working in health care who would love to explore meaning in medicine with us on the show, feel free to leave a suggestion in the comments or send an email to info@thedoctorsart.com.Copyright The Doctor's Art Podcast 2025

The gut is in the news. It's really in the news. Catapulted there from exciting developments coming from laboratories all around the world. Links of gut health with overall health are now quite clear and surprising connections are being discovered between gut health and things like dementia and Alzheimer's. But how does the gut communicate with other parts of the body in ways that make it this important, and where does the brain figure into all this? Well, there's some interesting science going on in this topic, and a leading person in this area is Dr. Diego Bohorquez. Dr. Bohorquez is the associate professor of medicine, of molecular genetics and microbiology and of cell biology at the Duke University School of Medicine. Interview Transcript Diego, your bio shows that you blend work in nutritional biochemistry, gastrointestinal physiology, and sensory neurobiology. It took me a little time to figure out just what these things are, but what this represents, to be a little more serious, is a unique ability to understand that the different parts of the body, the gut and the brain in particular, interact a lot. And you're in a very good position to understand how that happens. Let's dive in with the kind of a basic question. What got you interested in this interaction of the gut with the brain and why care about it? Yes. Kelly, I think that that's all technicalese for saying that we are at the interface of food, the gut, and the brain. Apart from the fact that we are what we eat and if we truly believe that then food will be shaping us. Not only our body, but also like our belief systems, our societal systems, and so on and so forth. I don't think that that is anything new. However, what is new is the ability of the gut to guide our decision making. And it was interesting to hear in your introduction that now the gut is all in the news. In 2005 when I came to the United States, and I was at North Carolina State University, and I joined a graduate school. I remember taking a graduate course in physiology in 2007. And when the professor opened the session on gastrointestinal physiology, he said the gut is one of the most misunderstood and mysterious organs. It has almost as many neurons as the spinal cord, or more. But honestly, we don't give a lot of respect to the gut. We only think that it does some digestion and absorption, and we judge it more for the value of its products of digestion than what it does for the entire body. And fast forward almost 20 years later now, partly my laboratory and other laboratories that have entered this field since some of our discoveries started to emerge, it's very clearly showing that the gut not only has its own sensory system that is behind what we call gut feelings. The gut feelings are actually real. But it actually can influence our decision making. Like specifically, we have shown that our ability to choose sugars and consume sugars and feel sugars and choose them over sweeteners, it can be pinpointed to a specific set of cells in the intestine called neuropod cells and specific receptors in those cells. And the intestine is right after the stomach. And this is where these cells are exposed to the surface of the gut and detect the chemical composition of food to guide our decision making. Let's talk about that a little bit more. So, you've got this axis, or this means of communication between the gut and the brain going on. And let's talk about how it affects what we eat. You just alluded to the fact that it's pretty important. What does it tell us? What to eat, how much to eat? What we like to eat? When we're hungry, when we've had enough? How does this affect our eating? We are beginning to understand how much it affects this eating. And obviously we are departing from understanding, right? And an understanding is cognitive. In the 1500s is when the idea of 'we think therefore we are,' came online. And we needed to think things before we actually will understand them. But well before thinking them, we actually feel them. And you probably have noticed that. If anybody offers you maybe a cup of water at 5:00 AM, 6:00 AM, it will be very welcome. Especially with it's a little bit warm. If they offer you a steak at 5:00 AM you will run away from that. But in fact, you'll create distress I think unless you are like severely jet lagged. And a lot of those feelings not only come from the experience, but even if you blind are blindfolded, your gut will be able to evaluate what you just ingested. And it is because the intestine, it is the point where those molecules in the meal or in the drink, will be either absorbed to become part of who we are, or will be excreting and expelled. And that absorption of who we are is dependent on the context. Like for instance, the part of the month, morning versus afternoon, health status, age, will influence specifically like at the molecular level, what it is that we need to continue to thrive. It sounds like there's lots of potential for the gut and its interaction with the brain working in concert with the rest of the body. Things are in balance and working like they should be. But there are lots of things going on out there that disrupt that. Tell us more about that and how it affects eating. For example, the levels of obesity have risen so much in the past decades. How does the gut figure into that, for example. Could there be environmental things like the microplastics or exposure to toxins like pesticides and things that might be affecting the gut that throws the system off? I think that that is a very timely question for the days. Over the last 10 years, we have documented that the gut has its own sensory system. And in fact, it's one of the most ancient sensory systems. At the very beginning, 600 million years ago, when cells started to coalesce into animals, multicellular organisms, they needed to eat. And they needed to not only find the food but create a sensory representation of the food. What do I mean by that? Eating algae is very different than eating bacteria, for instance. And the gut needed to have these sensors to be able to rapidly create first a representation, this is bacteria. And then put out the molecules to digest that bacterium or those bacteria. And then ultimately absorb them, turn them into metabolites and continue to thrive, right? Perhaps reproduce, coalesce and so on and so forth. This is a very important concept because our reality, the reality that you and I are having right now, it is guided by our senses. And we have multiple senses. Like for instance, we are able to communicate partly because of the sound that is going through our ears. And then there are inner hair cells that are picking up those waves. Passing that information to the brain, decoding it, and then the brain coalesces with everything else and saying like, 'okay, Diego, you're in a podcast. Make sure that you say something hopefully reasonable, right?' What the gut is doing, as a true sensory system, is also detecting the food that we have ingested, creating a rapid representation. It's not the reality itself. It is a representation of the reality. Because when we eat an apple, ultimately the gut, what it's doing is creating a representation that was an apple and not an orange. And then telling the brain, look, you're going to get some glucose, some fiber, a little bit of a skin. And you may need to adjust it with water, right? And then that will trigger the desire to, 'oh, maybe I should have also a cup of water.' Why does that have to do with, the societal issues that we are facing? Since the 1970s, we learned to disentangle the sensory experience of food, not only as humans or scientists, but also that was extrapolated to the society. So, if you go and look, and it is not a secret, it has been very well documented. For instance, the ability to put artificial sweeteners out there. It has really changed the health landscape. And it was just a normal progression of how it is that we humans think. We thought well, people consume sugars because they're sweet. If we take out the calorie and we just leave the sweetness, it will be totally fine because it's benign. You're not consuming anything else. However, the gut, you have promised the gut something sweet. That it has always, or almost always, invariably, been associated with a nutritional value. Then the gut is fed this information that is skewed. Then it has to go and adjust. And we actually have demonstrated that in the laboratory that when the neuro pods detect a non-caloric sweetener, they actually release a different neurotransmitter that communicates to the brain that artificial sweeteners have arrived at the gut, as opposed to glucose, which triggers the release of glutamate. And that glutamate is essential for the organism to know that we have consumed sugar. Is it safe to say then that the body has evolved to be able to have effective signaling and feedback systems with things that are found out there in nature, like sugar or an apple or an orange. But when you start introducing things that don't exist in nature, like the artificial sweeteners, then bad things can happen. Yes. Because imagine right now your brain will swap the reality and you will transport yourself or the beach. You may not even have the clothing ready to confront the breeze of the beach, right? Or the salt. You would have not been prepared, right? We evolved around nature because nature was there before us. Therefore, we had gradually adjusted to what nature had to offer. Eventually we introduced fire, and we were able to transform simple or complex carbohydrates into something digestible. And then the body had the ability to adjust to it. And not only the body, but also the microbiota in the gut. Now we are talking about like the transformation of foods. And especially I think in the last 30 years we have been able to transform those foods. Beverages have sweeteners now. We have energy drinks that have a composition of vitamins and other things. And while those things individually perhaps are not innocuous, we haven't explored what is the conglomerate effect on long-term health. When we talk about these things being added to foods, I mean, there are whole classes of things like colorings and dyes and artificial sweeteners and things. And then there are processing things that go on, like extrusion and different things that take something like wheat or corn and turn it into something that the body is not accustomed to dealing with. Is the body incapable of perceiving what these things are? Does it get send out wrong signals? Why should we be worried about these things? I don't think that we should be worried necessarily because that's alarming, right? But we should be aware, certainly, that the body keeps tabs on it. Something very simple. If you rub water on your skin versus if you rub oil on your skin, your brain already starts to perceive that substance as different. Now, imagine the gut is going to know exactly the same thing. It knows what water is. It knows what oil is. It knows what carbs are. It knows what protein is. And depending on what it has been fed for, thousands of years, it will be able to create that representation as I alluded to. And therefore, if there is a foreign composition, it's going to have to adjust to the situation. And that is how you can end up altering the composition of a regular body. Because like, for instance, in nature if you go and look at native populations that live very close to nature, you know, the body composition is in a certain form. But in cities where you're exposed to foods that have been transformed, the body composition is very different. And I'm not talking only about body weight, but also height, shape, you know. That certainly makes sense. You know, something that's been in the news a lot lately are the GLP1 drugs like Ozempic and Zepbound and they have very powerful effects on appetite, satiety, and weight regulation. How is the gut brain axis involved in this? I would like to make a couple of points in there.The first one is that glucagon-like peptide is obviously is very similar to glucagon. Glucagon is produced in the pancreas. Glucagon-like peptide is actually produced in the gut. And it is produced by these neuro pod cells that also produce some neurotransmitters. And it is produced in response to specific nutrients like glucose. And it is a signal glucagon like peptide 1. It is a signal for not only adjusting insulin release, but it is also a signal for coordinating what has arrived in the gut. It does affect motility. Eventually it is thought that goes into the bloodstream and affects the nervous system. However, and I said it is thought because the brain also produces glucagon-like peptide. There are cells in the skin. There are cells in the urethra. There are cells in the bladder. There are cell cells in the spinal cord in the choroid plexus that is exposed to the cerebral spinal fluid that also produces some of these peptides as signaling molecules. And I have to make that clarification because traditionally it has been thought to be a signal from the gut, per se. But these are just signaling molecules. The second part is that the arrival of Ozempic, I thought that it was obviously a very important step not only scientifically, but also societally. Why? Because up until 1980s and I have thought with many colleagues especially in medicine. And they will say like, when an obese patient will arrive in the office, first of all, there was not a lot of options. One of the recommendations is - are you doing enough dieting or exercise? And if the patient was like, you know, I'm not eating even a lot, but I'm gaining weight. Or it was perhaps psychosomatic because we didn't have the molecular language to be able to explain what was going on. I think that Ozempic clearly has shown that when we are affecting a set of receptors in the body, perhaps in the gut, it's changing many different things. Not only like food intake, but also alcohol intake and how people feel. I think that is definitely a breakthrough. Where are we going from here? I think that this is the beginning of a long conversation in which we are going to be looking for options not only to reduce the amount of food, but actually to steer food choices from the gut. Because the gut is still as an external surface. And that's what I've mentioned that the discovery that these neuro pot cells can guide our food choices, I think that is very attractive for future options on how we are going to steer decision making. So, let me ask a final question. You partly just answered it, but where do you see this field going? What are you excited about and what do you think the next frontiers will be? I think that I'm a little bit more close to nature. I think that on moving forward, there's all obviously a lot of technologies and molecules that are going to be developed to perhaps treat some disorders. Not only related to the body, but also to the mind. Chronic depression and so on and so forth. But I think a lot of these elements have already been explored in nature. And if we look back anthropologically, people were solving the issue of medicine with their environment. In fact, what we call metropolitan medicine evolved largely from natural medicine. And in fact, today, 80% of the world, they still rely directly on plants and other compounds that are directly from plants for healthcare. I think that there is a lot to learn in there and a lot to merge, especially with the new technologies on diagnostics. And I think that that's a very exciting area to keep nature in mind. And when I said nature is like our relationship with environment, right? Bio Diego V. Bohorquez is an associate professor of medicine, associate professor in molecular genetics and microbiology, associate professor of cell biology, associate research professor in neurobiology, and an associate professor in pathology at Duke University's Department of Medicine. Bohorquez is a gut-brain neuroscientist and holds a Ph.D. from North Carolina State University. His research focus is to unveil how the brain perceives what the gut feels, how food in the intestine is sensed by our body, and how a sensory signal from a nutrient is transformed into an electrical signal that alters behavior.

What can grief teach us about life, love, and healing? In this powerful episode, Dr. Gregg Korbon shares the extraordinary story of his son Brian, whose intuitive wisdom and passing transformed his understanding of challenge, spirituality, and resilience. Through raw honesty and profound insights, this conversation will help you see loss not as an end, but as a path to deeper meaning and lasting hope.

To read more of Derek's reporting on GLP-1 drugs, you can subscribe to his Substack here. GLP-1 drugs like Ozempic and Zepbound don't just help with Type 2 diabetes and weight loss. They seem to curb alcohol, cocaine, and tobacco use among addicts. In some studies, they prevent strokes, heart attacks, chronic kidney disease, sleep apnea, and Parkinson's disease. They're associated with a lower risk of several cancers, including pancreatic cancer and multiple myeloma. Arthritic patients on the drugs experienced relief from knee pain that was “on par with opioid drugs.” A small study found that they reduce migraine headaches by 50 percent. And emerging research suggests they might even slow the rate of memory loss among people diagnosed with Alzheimer's. Is all of this real? And if it's real, how is one drug doing so many different things? And if it is doing all those things, why shouldn't we be developing versions of the drug for just about everyone? Today we have two guests: David D'Alessio, chief of endocrinology and metabolism at the Duke University School of Medicine; and Randy Seeley, a professor of surgery, internal medicine, and nutritional sciences at the University of Michigan. We talk about how these drugs work—why they seem to do everything—and how our understanding of them could make them better, more effective, more broadly useful. If you have questions, observations, or ideas for future episodes, email us at PlainEnglish@Spotify.com. Host: Derek Thompson Guests: David D'Alessio and Randy Seeley Producer: Devon Baroldi Disclosure: Dr. Seeley has received research support from several pharmaceutical companies, including Eli Lilly, Diasome, and Amgen. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Ep. 58 DuEwa interviewed author and lawyer, Courtney Duke Foster about her novel. Visit www.courtneydukefoster.com for more information.Follow Nerdacity @nerdacityarts on InstagramX.com @nerdacitypod1Visit DuEwa's website at www.duewaworld.comBioCourtney is a lawyer who was bitten by the writer bug almost a decade ago. She has written dozens of poems and short stories. Her short stories have been published in the Bay to Ocean Journal and The Fire Inside, Vol. III. In 2022, Courtney published her debut novel, PASSING NOTES. She published the follow-up novel, RESULTS WILL VARY, in 2024. A graduate of Spelman College and Duke University School of Law, Courtney grew up in Maryland, where she lives with her two awesome daughters. In her spare time, she enjoys writing stories, of course, but also watching movies and attending musicals and comedy shows. She adores the art of storytelling in all forms. She loves writing stories that show the good, the bad, and the wondrous aspects of life and love with characters you wish you could hang out with.

if you have any feedback, please send us a text! Thank you!Dr. Ludwig Lin of the CSA Vital Times Podcast sits down with Dr. Adjoa Boateng Evans, a former Stanford ICU and anesthesia attending and now faculty at Duke University School of Medicine to discuss her pioneering work in bringing Humanities and personal expression into academic anesthesiology. She shares how this approach can help healthcare professionals navigate the stresses of our profession and build resilience. What inspired her to take this path? Tune in to find out. 

Dalbavancin, a long-acting IV lipoglycopeptide, may be an option for the treatment of complicated Staphylococcus aureus bacteremia without requiring long-term IV access. Author Thomas L. Holland, MD, MSc, from Duke University School of Medicine discusses key points of the DOTS randomized clinical trial and more with JAMA Deputy Editor Preeti Malani, MD, MSJ.Related Content: Dalbavancin for Treatment of Staphylococcus aureus BacteremiaManagement of Staphylococcus aureus Bacteremia

Dalbavancin, a long-acting IV lipoglycopeptide, may be an option for the treatment of complicated Staphylococcus aureus bacteremia without requiring long-term IV access. Author Thomas L. Holland, MD, MSc, from Duke University School of Medicine discusses key points of the DOTS randomized clinical trial and more with JAMA Deputy Editor Preeti Malani, MD, MSJ. Related Content: Dalbavancin for Treatment of Staphylococcus aureus Bacteremia Management of Staphylococcus aureus Bacteremia

In this episode of Value-Based Care Insights, host Daniel Marino continues the conversation on CMS's mandatory TEAM Model (Transforming Episode Accountability Model) — a five-year episode-based pricing initiative impacting 741 hospitals across the country. Joining the discussion is Dr. Christian Pean, a board-certified orthopedic trauma and reconstruction surgeon at Duke University School of Medicine, executive director of AI and Innovation for Duke Orthopedic Surgery, and co-founder/CEO of Revel AI Health. Together, they unpack the clinical and operational impacts of TEAM, with a focus on five key surgical procedures. Dr. Pean highlights how emerging technologies — including conversational AI platforms — are enhancing episode management and streamlining outreach, triage, and documentation to help providers improve care coordination and succeed under TEAM. 

Host Dan Marino continues the conversation on CMS's mandatory TEAM Model (Transforming Episode Accountability Model) — a five-year episode-based pricing initiative impacting 741 hospitals across the country. Joining the discussion is Dr. Christian Pean, a board-certified orthopedic trauma and reconstruction surgeon at Duke University School of Medicine, executive director of AI and Innovation for Duke Orthopedic Surgery, and co-founder/CEO of Revel AI Health. Together, they unpack the clinical and operational impacts of TEAM, with a focus on five key surgical procedures. Dr. Penn highlights how emerging technologies — including conversational AI platforms — are enhancing episode management and streamlining outreach, triage, and documentation to help providers improve care coordination and succeed under TEAM. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

A problem plagues modern healthcare: machines are setting the standard of care, and human clinicians are struggling to keep up. Artificial intelligence will only make this worse. The technical mindset fragments patient care and draws us further from shalom even as pursue surrogate markers that are meant to restore health. How can we, as Christian clinicians, respond wisely and well to this problem? One response is found in the story of the God's people in the Bible, specifically in the story of Israel's adoption into the family of God. The Theology, Medicine, and Culture Initiative (TMC) at Duke Divinity School and the Trent Center for Bioethics, Humanities & History of Medicine at Duke co-sponsored this seminar entitled "The Uncanny Valley: Remaining Human in Healthcare" on November 8, 2024 with Dr. Joshua Briscoe. Joshua Briscoe, MD is a Hospice and Palliative Care physician at the Durham VA Medical Center where he also serves on the Ethics Consultation Service. He's an assistant professor of Medicine and of Psychiatry and Behavioral Sciences at Duke University School of Medicine, and faculty associate with the Trent Center for Bioethics, Humanities and History of Medicine. He writes about issues at the intersection of medicine, technology, and moral formation in a monthly newsletter entitled Notes from a Family Meeting.

In this episode, Tracey L. Yap, RN, PhD, Professor at the Duke University School of Nursing and Senior Fellow in the Duke University Center for the Study of Aging and Human Development, discusses how to justify the cost of a pressure injury prevention program to your CFO. She shares insights on prevention's economic value, cultural buy-in, and practical strategies for implementation. This episode is sponsored by Smith+Nephew. 

The US leads the world in biomedical innovation, with about 40% of patents being filed by US scientists and companies. The FDA plays a critical role in supporting and enabling this innovation pipeline and our guest Dr. Robert Califf was commissioner of the agency not once, but twice under Presidents Obama and Biden. He joins us to talk about what Americans should know about FDA's critical role and the threats to its functioning from the dramatic cuts the Trump administration has made over the last three months.We discuss:The broad sweep of FDA's purview from drugs and medical devices to cosmetics, food, tobacco and dog foodConcern that the FDA is now “decapitated and eviscerated” from the massive and multiple rounds of dismissalsWhile most industries want less regulation, the pharma industry wants more information and guidance from the FDACaliff has been affiliated with Duke for 50 of its 100 years, but a part of his heart is still with ClemsonWhat would Califf's “Make America Healthy Again” agenda be?“We need to develop reliable, repetitive sources of information that help people do things that are healthy and beneficial. That part of MAHA I like a lot…The second thing is… I'm developing connections with people who are thinking differently about primary care because I think everybody agrees there's no way you can take the current workforce and deliver what's needed. So it's got to be linked up with AI and digital technologies, but also with a very different looking workforce that gets paid differently, has more respect.”Relevant LinksRead Califf's WSJ opinion letter: “Work with the Bureaucracy, Not Against It”Peter Marks' resignation letter NYT article on the impact of FDA layoffsCaliff's “Public Health on Call” podcast episode on the state of the FDA Opinion article from 7 previous FDA commissioners on how recent changes are undermining credibility of the FDAAbout Our GuestRobert M. Califf, MD served as FDA Commmissioner under Presidents Biden and Obama. Califf is a nationally recognized expert in cardiovascular medicine, health outcomes research, health care quality, and clinical research, and a leader in the growing field of translational research. Prior to rejoining the FDA in 2022, Califf was head of medical strategy and senior advisor at Alphabet, contributing to strategy and policy for its health subsidiaries Verily Life Sciences and Google Health. Prior to Alphabet, he was professor of medicine and vice chancellor for clinical and translational research at Duke University, director of the Duke Translational Medicine Institute, and founding director of the Duke Clinical Research Institute. Dr. Califf is a graduate of Duke University School of Medicine. He completed a residency in internal medicine at the University of California, San Francisco and a fellowship in cardiology at Duke.Connect With UsFor more information on...

Schenita D. Randolph. Dr. Schenita D. Randolph is an Associate Professor at Duke University School of Nursing and Founding Director of the HEEAT Lab, which stands for addressing Health disparities through Engagement, Equity, Advocacy and Trust. A registered nurse for over 25 years, Dr. Randolph is advancing nursing science by using community partnerships to address the health inequities among Black Families living in the United States south. Her work has received national attention in the popular media and has been supported by public and private funders. She has publications in numerous journals including the New England Journal of Medicine and the Journal of the American Medical Association, that highlight population health and community engagement in education and research. She is a Fellow in the American Academy of Nursing which represent nursing’s most accomplished leaders in policy, research, administration, practice, and academia. She is a proud HBCU graduate of North Carolina Agricultural and Technical (A&T) State University. Dr. Randolph is dedicated to partnering with the community to develop culturally and socially relevant interventions that will advance health equity and improve health outcomes for minoritized communities. She is also committed to mentoring and supporting the next generation of nurse leaders and scientists. Company Description * The HEEAT Lab is an interdisciplinary team of researchers, clinicians, business owners, and community members who are dedicated to addressing health disparities through equity, engagement, advocacy, and trust. #BEST #STRAW #SHMSSupport the show: https://www.steveharveyfm.com/See omnystudio.com/listener for privacy information.

Schenita D. Randolph. Dr. Schenita D. Randolph is an Associate Professor at Duke University School of Nursing and Founding Director of the HEEAT Lab, which stands for addressing Health disparities through Engagement, Equity, Advocacy and Trust. A registered nurse for over 25 years, Dr. Randolph is advancing nursing science by using community partnerships to address the health inequities among Black Families living in the United States south. Her work has received national attention in the popular media and has been supported by public and private funders. She has publications in numerous journals including the New England Journal of Medicine and the Journal of the American Medical Association, that highlight population health and community engagement in education and research. She is a Fellow in the American Academy of Nursing which represent nursing’s most accomplished leaders in policy, research, administration, practice, and academia. She is a proud HBCU graduate of North Carolina Agricultural and Technical (A&T) State University. Dr. Randolph is dedicated to partnering with the community to develop culturally and socially relevant interventions that will advance health equity and improve health outcomes for minoritized communities. She is also committed to mentoring and supporting the next generation of nurse leaders and scientists. Company Description * The HEEAT Lab is an interdisciplinary team of researchers, clinicians, business owners, and community members who are dedicated to addressing health disparities through equity, engagement, advocacy, and trust. #BEST #STRAW #SHMSSee omnystudio.com/listener for privacy information.

Schenita D. Randolph. Dr. Schenita D. Randolph is an Associate Professor at Duke University School of Nursing and Founding Director of the HEEAT Lab, which stands for addressing Health disparities through Engagement, Equity, Advocacy and Trust. A registered nurse for over 25 years, Dr. Randolph is advancing nursing science by using community partnerships to address the health inequities among Black Families living in the United States south. Her work has received national attention in the popular media and has been supported by public and private funders. She has publications in numerous journals including the New England Journal of Medicine and the Journal of the American Medical Association, that highlight population health and community engagement in education and research. She is a Fellow in the American Academy of Nursing which represent nursing’s most accomplished leaders in policy, research, administration, practice, and academia. She is a proud HBCU graduate of North Carolina Agricultural and Technical (A&T) State University. Dr. Randolph is dedicated to partnering with the community to develop culturally and socially relevant interventions that will advance health equity and improve health outcomes for minoritized communities. She is also committed to mentoring and supporting the next generation of nurse leaders and scientists. Company Description * The HEEAT Lab is an interdisciplinary team of researchers, clinicians, business owners, and community members who are dedicated to addressing health disparities through equity, engagement, advocacy, and trust. #BEST #STRAW #SHMSSteve Harvey Morning Show Online: http://www.steveharveyfm.com/See omnystudio.com/listener for privacy information.